ClinicalTrials.gg
CompletedNCT03227224Updated Apr 29, 2025Results posted

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Phase 2 interventional study of Placebo and JNJ-42847922 in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 101 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
5th of 12
287 · median 176
Started
2017
with 1 other
Phase 2
2 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.

Read the detailed description

The study will investigate the antidepressant effects of a range of doses of JNJ-42847922 (seltorexant) (versus placebo), as adjunctive treatment to antidepressant drugs for treatment of MDD, and will assess the safety and tolerability of JNJ-42847922. The study will be conducted in 3 phases: a screening phase (up to 4 weeks), a double-blind treatment phase (6 weeks), and a post-treatment follow-up phase (2 weeks). Efficacy, safety, pharmacokinetic, and biomarker evaluations will be performed in the study at defined timepoints. The duration of the study will be up to approximately 12 weeks (84 days).

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of non- (WONCBP), aged 18 to 70 years (inclusive). A WONCBP is defined as: a).: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. b). Permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy. c). If reproductive status is questionable, additional evaluation should be considered
  • Meet -5th Edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders- Clinical Trials Version (SCID-CT). In addition their major depressive episode must be deemed "valid" using the SCID Screening Questionnaire (SSQ) interview administered by remote, independent raters. The length of the current depressive episode must be less than or equal to (\<=) 18 months
  • Have had an inadequate response to at least 1 but no more than 3 antidepressants, administered at an adequate dose and duration in the current episode of depression, as measured by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ). An inadequate response is defined as less than (\<)50 percent (%) reduction in depressive symptom severity, as assessed by the MGH-ATRQ. An adequate trial is defined as an antidepressant treatment for at least 4 weeks at or above the minimum therapeutic dose specified in the MGH-ATRQ, for any particular antidepressant. The inadequate response must include the participant's current antidepressant treatment
  • Participants receiving monotherapy treatment for depressive symptoms with one of the following selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants, in any formulation: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above the minimum therapeutic dose level) for at least 4 weeks, and for no greater than 12 months, at screening. Modification of an effective preexisting therapy should not be made for the explicit purpose of entering a subject into the study
  • Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to (>=)25 (performed by independent, centralized remote raters) at screening and must not demonstrate a improvement (that is, an improvement of greater than [>]20% on their MADRS total score) from the screening to baseline visit
  • Must be otherwise healthy on the basis of physical examination, medical history, vital signs, 12-lead (ECG), and clinical laboratory tests performed at screening. If the results of the clinical laboratory tests are outside the normal reference ranges, the participant could be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Has a history of, or current signs and symptoms of, severe renal insufficiency ( \<30 milliliter per minute [mL/min]); moderate to severe hepatic insufficiency ( Score 7-9), significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic (including narcolepsy), hematologic, rheumatologic, immunologic or endocrine disorders (including uncontrolled hypo- or hyperthyroidism or diabetes, or insulin-dependent diabetes mellitus). Participants with non-insulin dependent diabetes mellitus who are well-controlled ( [HbA1C] \<=7.5% and fasting glucose \<126 milligram per deciliter [mg/dL] at screening) could be eligible to participate if otherwise medically healthy, and if on a stable regimen of glucose-lowering medications for at least 2 months prior to screening
  • Has signs and symptoms of Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the hypothalamic-pituitary-adrenal (HPA) axis
  • Has a history of lack of response to 3 or more adequate antidepressant treatments, as indicated by no or minimal (\<= 25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 4 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, mental retardation, autism spectrum disorder, or borderline personality disorder, somatoform disorders, chronic fatigue syndrome or fibromyalgia
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
287 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

    Drug: Placebo

  • Experimental
    JNJ-42847922

    Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

    Drug: JNJ-42847922

Interventions

  • DrugPlacebo

    Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

  • Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

    Also known as: MIN-202;, Seltorexant

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

    Time frame: Baseline to Week 6

  2. Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between the initial administration of study drug and 2 days after the last administration of study drug.

    Time frame: Up to Week 8

  3. Percentage of Participants With Clinically Significant Laboratory Abnormalities

    Percentage of participants with clinically significant laboratory abnormalities were reported which included Gamma-glutamyl transferase (GGT), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Albumin , bicarbonate, bilirubin, calcium, chloride, cholesterol, creatinine, direct bilirubin, glucose, high density lipoprotein (HDL) cholesterol, hemoglobin A1C, low density lipoprotein (LDL) cholesterol, phosphate, potassium, protein, sodium, triglycerides, urate, and urea nitrogen.

    Time frame: Up to Week 8

  4. Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8

    Change from baseline in vital signs (SBP and DBP) at Day 8 was reported.

    Time frame: Baseline and Day 8

  5. Change From Baseline in Vital Signs (SBP and DBP) at Day 22

    Change from baseline in vital signs (SBP and DBP) at Day 22 was reported.

    Time frame: Baseline and Day 22

  6. Change From Baseline in Vital Signs (SBP and DBP) at Day 42

    Change from baseline in vital signs (SBP and DBP) at Day 42 was reported.

    Time frame: Baseline and Day 42

  7. Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)

    Change from baseline in vital signs (SBP and DBP) at endpoint was reported.

    Time frame: Baseline and Endpoint (Week 6)

  8. Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8

    Change from baseline in vital sign (PR) at Day 8 was reported.

    Time frame: Baseline and Day 8

  9. Change From Baseline in Vital Sign (PR) at Day 22

    Change from baseline in vital sign (PR) at Day 22 was reported.

    Time frame: Baseline and Day 22

  10. Change From Baseline in Vital Sign (PR) at Day 42

    Change from baseline in vital sign (PR) at Day 42 was reported.

    Time frame: Baseline and Day 42

  11. Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)

    Change from baseline in vital sign (PR) at endpoint (Week 6) was reported.

    Time frame: Baseline and Endpoint (Week 6)

  12. Change From Baseline in Vital Sign (Temperature) at Day 8

    Change from baseline in vital Sign (temperature) at Day 8 was reported.

    Time frame: Baseline and Day 8

  13. Change From Baseline in Vital Sign (Temperature) at Day 22

    Change from baseline in vital Sign (temperature) at Day 22 was reported.

    Time frame: Baseline and Day 22

  14. Change From Baseline in Vital Sign (Temperature) at Day 42

    Change from baseline in vital Sign (temperature) at Day 42 was reported.

    Time frame: Baseline and Day 42

  15. Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)

    Change from baseline in vital Sign (temperature) at endpoint (Week 6) was reported.

    Time frame: Baseline and Endpoint (Week 6)

  16. Change From Baseline in Physical Examination (Waist Circumference) at Day 42

    Change from baseline in physical examination (waist circumference) was reported.

    Time frame: Baseline and Day 42

  17. Change From Baseline in Physical Examination (Body Weight) at Day 42

    Change from baseline in physical examination (body weight) was reported.

    Time frame: Baseline and Day 42

  18. Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42

    Change from baseline in physical examination (BMI) was reported.

    Time frame: Baseline and Day 42

  19. Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined Limits

    Percentage of participants with treatment-emergent abnormal ECG values (Heart rate less than or equal to \[\<=\] 50 or greater than or equal to \[\>=\] 100 beats per minute \[bpm\], PR interval \<=120 or \>=200 milliseconds \[msec\], QRS interval \<=60 or \>=120 msec, and QT interval \<=200 or \>=500 msec) outside pre-defined limits were reported.

    Time frame: Up to Week 6

  20. Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.

    Time frame: Up to Week 8

  21. Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42

    Effect on sexual functioning was assessed using the ASEX score. The ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.

    Time frame: Baseline and Day 42

  22. Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43

    Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.

    Time frame: Day 43

  23. Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56

    Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.

    Time frame: Day 49 to Day 56

Secondary outcomes

  1. Change From Baseline in the MADRS Total Score by Baseline Insomnia Severity Index (ISI) Score at Day 42

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

    Time frame: Baseline and Day 42

  2. Change From Baseline in ISI Total Score at DB Endpoint (Up to Week 6)

    The ISI is a commonly used, 7-item psychometrically validated measure used to rate insomnia. Each item is scored 0 (no problem) to 4 (very big problem) with total between 0-28 which is calculated by adding the scores of all 7 items (absence of insomnia \[0-7\]; sub-threshold insomnia \[8-14\]; moderate insomnia \[15-21\]; and severe insomnia \[22-28\]). The change in ISI total score from baseline at DB endpoint was evaluated. Negative change in score indicates improvement.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  3. Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score

    Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.

    Time frame: Day 42

  4. Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score

    Participants with a MADRS total score of less than or equal to (\<=) 8, \<=10, and \<=12 at a given time point were considered as remitters. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.

    Time frame: Day 42

  5. Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42

    HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.

    Time frame: Baseline and Day 42

  6. Percentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score

    Participants with a \>=50 percent improvement in the HAM-A total score from baseline at a given timepoint were considered as responders. HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Participants with missing values at a given time point were imputed as non-responders.

    Time frame: Day 42

  7. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6)

    The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  8. Change From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42

    The SDS is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The scores for the first 3 items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has 1 item on days lost from school or work and 1 item on days when underproductive. Negative change in score indicates improvement.

    Time frame: Baseline and Day 42

  9. Change From Baseline in the MADRS Total Score at Day 42 in Participants With Major Depressive Disorder (MDD) With Anxious Distress Versus Participants With MDD Without Anxious Distress

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline and Day 42

  10. Change From Baseline in Salivary Cortisol Levels, Measured Upon Awakening at Days 8, 22 and 42

    Exposure on the hypothalamic-pituitary-adrenal (HPA) axis in participants with MDD was evaluated by assessing change in salivary cortisol levels.

    Time frame: Baseline, Days 8, 22 and 42

  11. Plasma Concentrations of Seltorexant and Its Metabolites (M12 and M16)

    Plasma concentrations of Seltorexant and its metabolites (M12 and M16) over time were reported.

    Time frame: Day 1: Between 0.25 hours (h) to 1.5 hour, 2 to 4 hours, and 6 to 8 hours post-dose; Day 8 (morning): 6 to 12 hours post evening dose of Day 7

  12. Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6)

    The PHQ-9 is a 9-item, Patient Reported Outcome (PRO) measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participants item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  13. Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6)

    The SHAPS is a 14-item, self-report instrument to assess hedonic capacity in adults with MDD. Each of the items has a set of 4 response categories-Definitely Agree (=1), Agree (=2), Disagree (=3), and Definitely Disagree (=4). A total score is created with either of the Disagree responses receiving a score of 1 and either of the Agree responses receiving a score of 0. The participants item responses are summed to provide a total score ranging from 0 to 14. A higher total SHAPS score indicates higher levels of current anhedonia.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  14. Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6)

    The PROMIS-SD Short Form subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  15. Change From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6)

    The PROMIS-Fatigue Short Form subscale consists of a static 8 item questionnaire. It assesses a range of symptoms from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Ratings are done on a 5-item Likert scale ranging from 0 (not at all) to 5 (very much) or 0 (never) to 5(always) depending upon the question answered. Higher scores on the PROMIS-F indicate more of the concept measured (fatigue). Negative change in score indicates improvement.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  16. Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6)

    The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  17. Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6)

    EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D-5L dimensions were scored using a utility-weighted algorithm to derive an EQ-5D-5L health status index score between 0 (death) to 100 (full health).

    Time frame: Baseline and DB Endpoint (Up to Week 6)

  18. Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6)

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-5D-5L (describing and valuing health-related quality of life) descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. Higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: Baseline and Endpoint (up to Week 6)

  19. Change From Baseline in Work Productivity and Limitations Using the Work Limitations Questionnaire (WLQ) Short Form Score at DB Endpoint (Up to Week 6)

    The WLQ is to assess the on-the-job impact of chronic health problems and/or treatment ("work limitations") in adults. It is a 8-item questionnaire self-report rating scale developed to measure the on-the-job impact of chronic health problems and/or treatment ("work limitations"). It comprises five dimensions of limitations: handling time, physical, mental-interpersonal, productivity loss and output demands. Participants respond to each item with options ranging from 'Almost all of the time' to 'none of the time', or 'Does not apply to my job'. Each dimension of limitations have a scale score ranging from 0 to 100 with lower score indicating low level of work limitations.

    Time frame: Baseline and DB Endpoint (Up to Week 6)

07

Results

Posted Feb 7, 2022

Participant flow

Double-blind Treatment Period (6 Weeks)
Participant flow — Double-blind Treatment Period (6 Weeks)
MilestonePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Started138336353
Treated137336152
Completed123275546
Not completed15687
Withdrew: Lost to follow-up1020
Withdrew: Protocol violation2200
Withdrew: Withdrawal by subject3232
Withdrew: Lack of efficacy1000
Withdrew: Received a disallowed concomitant treatment0010
Withdrew: Adverse event2114
Withdrew: Non-compliance with study drug2101
Withdrew: Other4010
Follow-up Phase (2 Weeks)
Participant flow — Follow-up Phase (2 Weeks)
MilestonePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Started138336353
Completed134295750
Not completed4463
Withdrew: Other4463

Outcome measures

PrimaryChange From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

Time frame:
Baseline to Week 6
Reported as:
Mean · score on a scale
Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-12.3 ± 10.95-12.2 ± 8.33-15.0 ± 12.13-14.7 ± 13.29
Statistical analysis
  • Placebo vs Seltorexant 10 mg · Mixed model for repeated measures (MMRM) · p = 0.724 · Difference of least square means: 0.9 · 90% CI -3.12 to 4.82
  • Placebo vs Seltorexant 20 mg · MMRM · p = 0.083 · Difference of least square means: -3.1 · 90% CI -6.13 to -0.16
  • Placebo vs Seltorexant 40 mg · MMRM · p = 0.424 · Difference of least square means: -1.5 · 90% CI -4.70 to 1.63
PrimaryPercentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between the initial administration of study drug and 2 days after the last administration of study drug.

Time frame:
Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability40.933.341.036.5
PrimaryPercentage of Participants With Clinically Significant Laboratory Abnormalities

Percentage of participants with clinically significant laboratory abnormalities were reported which included Gamma-glutamyl transferase (GGT), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Albumin , bicarbonate, bilirubin, calcium, chloride, cholesterol, creatinine, direct bilirubin, glucose, high density lipoprotein (HDL) cholesterol, hemoglobin A1C, low density lipoprotein (LDL) cholesterol, phosphate, potassium, protein, sodium, triglycerides, urate, and urea nitrogen.

Time frame:
Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Laboratory Abnormalities
percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
ALT: Abnormally high0001.9
Albumin: Abnormally low0000
Albumin: Abnormally high0000
ALP: Abnormally high0000
AST: Abnormally high0000
Bicarbonate: Abnormally low0000
Bicarbonate: Abnormally high0000
Bilirubin: Abnormally high0000
Calcium: Abnormally low0000
Calcium: Abnormally high0000
Chloride: Abnormally low0.7000
Chloride: Abnormally high0000
Cholesterol: Abnormally high0000
CK: Abnormally high001.70
Creatinine: Abnormally high0000
Direct Bilirubin: Abnormally high0000
GGT: Abnormally high0000
Glucose: Abnormally low0000
Glucose: Abnormally high0000
HDL Cholesterol: Abnormally low2.36.91.82.0
Hemoglobin A1C: Abnormally low0.0000
Hemoglobin A1C: Abnormally high0000
LDL Cholesterol: Abnormally low4.610.39.35.9
LDL Cholesterol: Abnormally high7.66.91.911.8
LDH: Abnormally high0000
Phosphate: Abnormally low0.73.23.37.8
Phosphate: Abnormally high0000
Potassium: Abnormally low0000
Potassium: Abnormally high0.73.200
Protein:Abnormally low0000
Sodium: Abnormally low0000
Sodium: Abnormally high0000
Triglycerides: Abnormally high0000
Urate: Abnormally low0000
Urate: Abnormally high005.01.9
Urea Nitrogen: Abnormally high0000
PrimaryChange From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8

Change from baseline in vital signs (SBP and DBP) at Day 8 was reported.

Time frame:
Baseline and Day 8
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8
millimeters of mercury (mmHg)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing DBP-0.7 ± 6.29-0.5 ± 5.220.7 ± 5.860.9 ± 6.41
Standing SBP-0.4 ± 8.16-0.8 ± 7.190.2 ± 8.170.3 ± 9.71
Supine DBP-0.8 ± 6.32-0.9 ± 6.192.3 ± 6.141.2 ± 6.67
Supine SBP0.1 ± 8.191.6 ± 6.561.5 ± 9.570.5 ± 10.19
PrimaryChange From Baseline in Vital Signs (SBP and DBP) at Day 22

Change from baseline in vital signs (SBP and DBP) at Day 22 was reported.

Time frame:
Baseline and Day 22
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (SBP and DBP) at Day 22
mmHgPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing DBP0.0 ± 6.67-1.2 ± 5.92-0.4 ± 6.902.4 ± 7.42
Standing SBP0.2 ± 7.01-1.2 ± 6.55-2.7 ± 9.621.6 ± 11.29
Supine DBP-0.4 ± 6.81-1.8 ± 6.7-0.2 ± 7.412.6 ± 6.81
Supine SBP0.8 ± 8.140.3 ± 4.76-0.9 ± 10.782.2 ± 10.08
PrimaryChange From Baseline in Vital Signs (SBP and DBP) at Day 42

Change from baseline in vital signs (SBP and DBP) at Day 42 was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (SBP and DBP) at Day 42
mmHgPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing DBP-0.5 ± 6.220.3 ± 9.16-0.8 ± 6.752.9 ± 7.96
Standing SBP-0.5 ± 7.991.1 ± 7.92-3.2 ± 10.572.0 ± 9.9
Supine DBP-0.6 ± 7.1-1.6 ± 9.230.0 ± 8.312.1 ± 7.5
Supine SBP0.6 ± 8.88-0.5 ± 10.00-1.3 ± 10.851.9 ± 8.35
PrimaryChange From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)

Change from baseline in vital signs (SBP and DBP) at endpoint was reported.

Time frame:
Baseline and Endpoint (Week 6)
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)
mmHgPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing DBP-0.3 ± 6.290.6 ± 8.98-0.6 ± 6.782.8 ± 7.79
Standing SBP-0.3 ± 8.331.0 ± 7.42-3.1 ± 10.291.8 ± 9.89
Supine DBP-0.4 ± 7.08-1.4 ± 9.340.2 ± 8.352.3 ± 7.39
Supine SBP0.6 ± 8.81-0.3 ± 9.38-1.4 ± 10.521.6 ± 8.58
PrimaryChange From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8

Change from baseline in vital sign (PR) at Day 8 was reported.

Time frame:
Baseline and Day 8
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8
Beats per minutePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing PR-0.1 ± 7.95-0.7 ± 7.070.9 ± 9.171.3 ± 9.21
Supine PR0 ± 7.15-1.2 ± 7.160.5 ± 6.231.7 ± 9.32
PrimaryChange From Baseline in Vital Sign (PR) at Day 22

Change from baseline in vital sign (PR) at Day 22 was reported.

Time frame:
Baseline and Day 22
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign (PR) at Day 22
Beats per minutePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing PR1.4 ± 7.570.7 ± 7.361.5 ± 8.270.3 ± 9.59
Supine PR1.5 ± 7.61-0.7 ± 7.312.8 ± 7.940.9 ± 10.55
PrimaryChange From Baseline in Vital Sign (PR) at Day 42

Change from baseline in vital sign (PR) at Day 42 was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign (PR) at Day 42
Beats per minutePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing PR0.8 ± 7.99-1.4 ± 9.351.5 ± 8.99-0.6 ± 9.04
Supine PR0.3 ± 8.16-2.8 ± 8.672.4 ± 9.01-0.6 ± 9.71
PrimaryChange From Baseline in Vital Sign (PR) at Endpoint (Week 6)

Change from baseline in vital sign (PR) at endpoint (Week 6) was reported.

Time frame:
Baseline and Endpoint (Week 6)
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)
Beats per minutePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Standing PR0.4 ± 8.4-1.6 ± 9.272.1 ± 9.34-0.5 ± 9.11
Supine PR0.2 ± 8.16-2.4 ± 8.972.4 ± 8.78-0.5 ± 9.60
PrimaryChange From Baseline in Vital Sign (Temperature) at Day 8

Change from baseline in vital Sign (temperature) at Day 8 was reported.

Time frame:
Baseline and Day 8
Reported as:
Mean · Celsius
Change From Baseline in Vital Sign (Temperature) at Day 8
CelsiusPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Vital Sign (Temperature) at Day 8-0.01 ± 0.324-0.05 ± 0.2740.02 ± 0.2780.06 ± 0.300
PrimaryChange From Baseline in Vital Sign (Temperature) at Day 22

Change from baseline in vital Sign (temperature) at Day 22 was reported.

Time frame:
Baseline and Day 22
Reported as:
Mean · Celsius
Change From Baseline in Vital Sign (Temperature) at Day 22
CelsiusPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Vital Sign (Temperature) at Day 22-0.02 ± 0.299-0.01 ± 0.242-0.02 ± 0.3320.02 ± 0.392
PrimaryChange From Baseline in Vital Sign (Temperature) at Day 42

Change from baseline in vital Sign (temperature) at Day 42 was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · Celsius
Change From Baseline in Vital Sign (Temperature) at Day 42
CelsiusPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Vital Sign (Temperature) at Day 420.02 ± 0.326-0.04 ± 0.291-0.05 ± 0.2230.05 ± 0.445
PrimaryChange From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)

Change from baseline in vital Sign (temperature) at endpoint (Week 6) was reported.

Time frame:
Baseline and Endpoint (Week 6)
Reported as:
Mean · Celsius
Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)
CelsiusPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)0.02 ± 0.317-0.03 ± 0.276-0.06 ± 0.2420.06 ± 0.437
PrimaryChange From Baseline in Physical Examination (Waist Circumference) at Day 42

Change from baseline in physical examination (waist circumference) was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · centimeters (cm)
Change From Baseline in Physical Examination (Waist Circumference) at Day 42
centimeters (cm)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Physical Examination (Waist Circumference) at Day 420.31 ± 2.778-0.50 ± 1.9720.00 ± 3.523-0.48 ± 9.498
PrimaryChange From Baseline in Physical Examination (Body Weight) at Day 42

Change from baseline in physical examination (body weight) was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · Kilograms (kg)
Change From Baseline in Physical Examination (Body Weight) at Day 42
Kilograms (kg)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Physical Examination (Body Weight) at Day 420.19 ± 2.3730.01 ± 1.8890.05 ± 1.5630.61 ± 1.946
PrimaryChange From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42

Change from baseline in physical examination (BMI) was reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · kilograms per meter square (kg/m^2)
Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42
kilograms per meter square (kg/m^2)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 420.07 ± 0.8500.01 ± 0.6620.02 ± 0.5530.22 ± 0.715
PrimaryPercentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined Limits

Percentage of participants with treatment-emergent abnormal ECG values (Heart rate less than or equal to \[\<=\] 50 or greater than or equal to \[\>=\] 100 beats per minute \[bpm\], PR interval \<=120 or \>=200 milliseconds \[msec\], QRS interval \<=60 or \>=120 msec, and QT interval \<=200 or \>=500 msec) outside pre-defined limits were reported.

Time frame:
Up to Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined Limits
percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Heart rate (<=50)0.703.46.0
Heart rate (>=100)0.701.70
PR interval (<=120)0.7000
PR interval (>=200)0.701.76.0
QRS interval (<=60)0000
QRS interval (>=120)03.300
QT interval (<=200)0000
QT interval (>=500)03.300
PrimaryPercentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.

Time frame:
Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)
percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
No Event94.996.996.794.1
Suicidal ideation5.13.13.35.9
Suicidal behavior0000
PrimaryChange From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42

Effect on sexual functioning was assessed using the ASEX score. The ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.

Time frame:
Baseline and Day 42
Reported as:
Mean · score on a scale
Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42
score on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42-1.4 ± 4.55-2.2 ± 3.62-2.4 ± 4.55-2.5 ± 4.94
PrimaryPhysician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43

Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.

Time frame:
Day 43
Reported as:
Mean · score on a scale
Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43
score on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 430.9 ± 1.680.2 ± 0.60.7 ± 1.60.5 ± 0.87
SecondaryChange From Baseline in the MADRS Total Score by Baseline Insomnia Severity Index (ISI) Score at Day 42

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

Time frame:
Baseline and Day 42
Reported as:
Mean · score on a scale
Change From Baseline in the MADRS Total Score by Baseline Insomnia Severity Index (ISI) Score at Day 42
score on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Day 42: Baseline ISI score per IWRS less than (<)15-13.3 ± 10.83-12.6 ± 8.01-13.0 ± 11.38-14.9 ± 12.14
Day 42: Baseline ISI score per IWRS>=15-11.6 ± 11.06-10.4 ± 10.41-16.5 ± 12.62-14.6 ± 13.87
SecondaryChange From Baseline in ISI Total Score at DB Endpoint (Up to Week 6)

The ISI is a commonly used, 7-item psychometrically validated measure used to rate insomnia. Each item is scored 0 (no problem) to 4 (very big problem) with total between 0-28 which is calculated by adding the scores of all 7 items (absence of insomnia \[0-7\]; sub-threshold insomnia \[8-14\]; moderate insomnia \[15-21\]; and severe insomnia \[22-28\]). The change in ISI total score from baseline at DB endpoint was evaluated. Negative change in score indicates improvement.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in ISI Total Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in ISI Total Score at DB Endpoint (Up to Week 6)-6.3 ± 6.73-4.9 ± 6.22-8.7 ± 6.91-8.5 ± 8.73
SecondaryPercentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score

Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.

Time frame:
Day 42
Reported as:
Number · Percentage of participants
Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score
Percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score28.524.241.038.5
SecondaryPercentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score

Participants with a MADRS total score of less than or equal to (\<=) 8, \<=10, and \<=12 at a given time point were considered as remitters. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.

Time frame:
Day 42
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score
Percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
MADRS (<=12)19.015.229.526.9
MADRS (<=10)17.59.126.226.9
MADRS (<=8)16.16.123.019.2
SecondaryChange From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42

HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.

Time frame:
Baseline and Day 42
Reported as:
Mean · Units on a scale
Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42-8.7 ± 7.92-9.9 ± 5.57-9.6 ± 9.31-9.9 ± 10.17
SecondaryPercentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score

Participants with a \>=50 percent improvement in the HAM-A total score from baseline at a given timepoint were considered as responders. HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Participants with missing values at a given time point were imputed as non-responders.

Time frame:
Day 42
Reported as:
Number · Percentage of participants
Percentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score
Percentage of participantsPlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Percentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score37.257.650.846.2
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6)

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Median · Units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6)-1.0 (-5 to 2)-1.0 (-3 to 1)-1.0 (-5 to 1)-1.0 (-5 to 1)
SecondaryChange From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42

The SDS is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The scores for the first 3 items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has 1 item on days lost from school or work and 1 item on days when underproductive. Negative change in score indicates improvement.

Time frame:
Baseline and Day 42
Reported as:
Mean · Units on a scale
Change From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42-7.9 ± 6.99-7.5 ± 5.19-7.9 ± 7.46-5.9 ± 9.20
SecondaryChange From Baseline in the MADRS Total Score at Day 42 in Participants With Major Depressive Disorder (MDD) With Anxious Distress Versus Participants With MDD Without Anxious Distress

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline and Day 42
Reported as:
Mean · Units on a scale
Change From Baseline in the MADRS Total Score at Day 42 in Participants With Major Depressive Disorder (MDD) With Anxious Distress Versus Participants With MDD Without Anxious Distress
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
MDD with Anxious Distress-13.9 ± 11.50-11.0 ± 8.67-16.9 ± 12.31-15.3 ± 13.0
MDD without Anxious distress-9.7 ± 9.59-13.4 ± 8.15-12.5 ± 11.70-13.8 ± 14.63
SecondaryChange From Baseline in Salivary Cortisol Levels, Measured Upon Awakening at Days 8, 22 and 42

Exposure on the hypothalamic-pituitary-adrenal (HPA) axis in participants with MDD was evaluated by assessing change in salivary cortisol levels.

Time frame:
Baseline, Days 8, 22 and 42
Reported as:
Mean · nanomoles per Liter (nmol/L)
Change From Baseline in Salivary Cortisol Levels, Measured Upon Awakening at Days 8, 22 and 42
nanomoles per Liter (nmol/L)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change at Day 80.2 ± 8.410.7 ± 7.240.0 ± 8.64-0.4 ± 6.19
Change at Day 220.4 ± 8.652.1 ± 6.390.7 ± 6.751.0 ± 10.75
Change at Day 421.0 ± 10.851.5 ± 6.15-1.2 ± 6.67-0.5 ± 6.69
SecondaryPlasma Concentrations of Seltorexant and Its Metabolites (M12 and M16)

Plasma concentrations of Seltorexant and its metabolites (M12 and M16) over time were reported.

Time frame:
Day 1: Between 0.25 hours (h) to 1.5 hour, 2 to 4 hours, and 6 to 8 hours post-dose; Day 8 (morning): 6 to 12 hours post evening dose of Day 7
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of Seltorexant and Its Metabolites (M12 and M16)
nanograms per milliliter (ng/mL)Seltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Seltorexant: Day 1, 0.25h-1.5h181 ± 165277 ± 291535 ± 500
Seltorexant: Day 1, 2-4h199 ± 113374 ± 232647 ± 325
Seltorexant: Day 1, 6-8h117 ± 99.3167 ± 179207 ± 169
Seltorexant: Day 8, Morning (6 to 12 hours post evening dose of Day 7)52.8 ± 65.869.4 ± 119104 ± 203
M12: Day 1,0.25h-1.5h118 ± 107194 ± 223357 ± 367
M12: Day 1, 2-4h146 ± 58.8283 ± 185513 ± 284
M12: Day 1, 6-8h105 ± 73.5187 ± 189279 ± 278
M12: Day 8, Morning (6 to 12 hours post evening dose of Day 7)76.2 ± 7999 ± 133169 ± 251
M16: Day 1, 0.25h-1.5h29.1 ± 30.247 ± 53.471.4 ± 78.3
M16: Day 1, 2-4h33.3 ± 15.761.4 ± 35.7101 ± 49.3
M16: Day 1, 6-8h27.5 ± 16.640.1 ± 31.470.6 ± 33.6
M16: Day 8, Morning (6 to 12 hours post evening dose of Day 7)23.7 ± 14.937.6 ± 36.161.7 ± 43.7
SecondaryChange From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6)

The PHQ-9 is a 9-item, Patient Reported Outcome (PRO) measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participants item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6)-7.3 ± 6.14-6.2 ± 5.48-8.6 ± 6.66-7.0 ± 7.64
SecondaryChange From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6)

The SHAPS is a 14-item, self-report instrument to assess hedonic capacity in adults with MDD. Each of the items has a set of 4 response categories-Definitely Agree (=1), Agree (=2), Disagree (=3), and Definitely Disagree (=4). A total score is created with either of the Disagree responses receiving a score of 1 and either of the Agree responses receiving a score of 0. The participants item responses are summed to provide a total score ranging from 0 to 14. A higher total SHAPS score indicates higher levels of current anhedonia.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6)-3.6 ± 4.44-2.3 ± 4.09-4.2 ± 4.50-3.2 ± 5.20
SecondaryChange From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6)

The PROMIS-SD Short Form subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6)-6.4 ± 8.53-5.1 ± 8.39-10.2 ± 9.21-10.9 ± 9.25
SecondaryChange From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6)

The PROMIS-Fatigue Short Form subscale consists of a static 8 item questionnaire. It assesses a range of symptoms from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Ratings are done on a 5-item Likert scale ranging from 0 (not at all) to 5 (very much) or 0 (never) to 5(always) depending upon the question answered. Higher scores on the PROMIS-F indicate more of the concept measured (fatigue). Negative change in score indicates improvement.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6)-7.7 ± 8.45-7.4 ± 8.25-9.4 ± 8.62-8.0 ± 10.29
SecondaryChange From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6)

The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Median · Units on a scale
Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6)-1.0 (-3 to 2)0.0 (-2 to 1)-1.0 (-3 to 1)-1.0 (-3 to 1)
SecondaryChange From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6)

EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D-5L dimensions were scored using a utility-weighted algorithm to derive an EQ-5D-5L health status index score between 0 (death) to 100 (full health).

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6)0.188 ± 0.22010.143 ± 0.18560.229 ± 0.20840.158 ± 0.2841
SecondaryChange From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6)

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-5D-5L (describing and valuing health-related quality of life) descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. Higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

Time frame:
Baseline and Endpoint (up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6)17.4 ± 20.558.9 ± 19.3423.4 ± 21.1820.1 ± 23.08
SecondaryChange From Baseline in Work Productivity and Limitations Using the Work Limitations Questionnaire (WLQ) Short Form Score at DB Endpoint (Up to Week 6)

The WLQ is to assess the on-the-job impact of chronic health problems and/or treatment ("work limitations") in adults. It is a 8-item questionnaire self-report rating scale developed to measure the on-the-job impact of chronic health problems and/or treatment ("work limitations"). It comprises five dimensions of limitations: handling time, physical, mental-interpersonal, productivity loss and output demands. Participants respond to each item with options ranging from 'Almost all of the time' to 'none of the time', or 'Does not apply to my job'. Each dimension of limitations have a scale score ranging from 0 to 100 with lower score indicating low level of work limitations.

Time frame:
Baseline and DB Endpoint (Up to Week 6)
Reported as:
Mean · Units on a scale
Change From Baseline in Work Productivity and Limitations Using the Work Limitations Questionnaire (WLQ) Short Form Score at DB Endpoint (Up to Week 6)
Units on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Time management-21.3 ± 30.41-18.2 ± 28.28-21.8 ± 34.46-20.8 ± 37.48
Physical demands-15.2 ± 23.64-23.5 ± 26.10-11.7 ± 31.4-14.3 ± 35.37
Mental interpersonal scale-21.2 ± 27.61-19.5 ± 25.28-26.28 ± 27.89-15.9 ± 31.76
Output demand scale-23.9 ± 26.72-22.2 ± 27.8-20.3 ± 30.08-21.7 ± 35.80
Productivity loss-5.1 ± 5.56-4.7 ± 5.30-4.7 ± 6.16-4.6 ± 7.02
PrimaryPhysician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56

Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.

Time frame:
Day 49 to Day 56
Reported as:
Mean · score on a scale
Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56
score on a scalePlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mg
Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 560.9 ± 1.910.4 ± 0.780.8 ± 1.640.7 ± 1.25

Adverse events

Collected over Up to Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/137 (0%)1/137 (0.7%)22/137 (16.1%)
Double-blind: Seltorexant 10 mg0/33 (0%)0/33 (0%)5/33 (15.2%)
Double-blind: Seltorexant 20 mg0/61 (0%)0/61 (0%)11/61 (18%)
DB: Seltorexant 40 mg0/52 (0%)0/52 (0%)12/52 (23.1%)
Follow-up: Placebo0/137 (0%)0/137 (0%)1/137 (0.7%)
Follow-up: Seltorexant 10 mg0/33 (0%)0/33 (0%)0/33 (0%)
Follow-up: Seltorexant 20 mg0/61 (0%)0/61 (0%)0/61 (0%)
Follow-up: Seltorexant 40 mg0/52 (0%)0/52 (0%)1/52 (1.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboDouble-blind: Seltorexant 10 mgDouble-blind: Seltorexant 20 mgDB: Seltorexant 40 mgFollow-up: PlaceboFollow-up: Seltorexant 10 mgFollow-up: Seltorexant 20 mgFollow-up: Seltorexant 40 mg
Polycythaemia VeraNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1370/330/610/520/1370/330/610/52
Most frequent other events
Most frequent other events
EventPlaceboDouble-blind: Seltorexant 10 mgDouble-blind: Seltorexant 20 mgDB: Seltorexant 40 mgFollow-up: PlaceboFollow-up: Seltorexant 10 mgFollow-up: Seltorexant 20 mgFollow-up: Seltorexant 40 mg
HeadacheNervous system disorders9/1372/331/616/520/1370/330/610/52
SomnolenceNervous system disorders7/1371/336/612/520/1370/330/610/52
NauseaGastrointestinal disorders4/1371/334/613/521/1370/330/610/52
InsomniaPsychiatric disorders1/1372/331/612/520/1370/330/611/52
DiarrhoeaGastrointestinal disorders7/1370/330/611/520/1370/330/610/52

Baseline characteristics

Full analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
Mean49.6 ± 11.7149.4 ± 15.3148.5 ± 13.5648.3 ± 10.5249.1 ± 12.34
Age, Customized
Age, Customized(Participants)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
Adults (18-64 years)131295951270
From 65 to 84 years642113
85 years and over00000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
Female74203028152
Male63133124131
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
Asian2039840
Black or African American1112519
Native Hawaiian or Other Pacific Islander10001
White105295039223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
Hispanic or Latino1515728
Not Hispanic or Latino120315342246
Unknown or Not Reported21339
Region of Enrollment
Region of Enrollment(Participants)PlaceboSeltorexant 10 mgSeltorexant 20 mgSeltorexant 40 mgTotal
BULGARIA352171266
FINLAND311510
GERMANY01113
JAPAN1838837
RUSSIAN FEDERATION18168345
UKRAINE2266539
UNITED STATES414201883
08

Study locations

101 sites
  • California Pharmaceutical Research Institute, Inc.
    Anaheim, California 92804, United States
  • Catalina Research Institute
    Chino, California 91710, United States
  • Synergy Clinical Research Center Of Escondido
    Lemon Grove, California 91945, United States
  • Asclepes Research
    Panorama City, California 91402, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • SF-Care, Inc
    San Rafael, California 94901, United States
  • Collaborative NeuroScience Network
    Torrance, California 90502, United States
  • Elite Clinical Trials
    Wildomar, California 92595-7007, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale Beach, Florida 33009, United States
  • Clinical NeuroScience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Innovative Clinical Research Inc
    Lauderhill, Florida 33319, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Qps-Mra, Llc
    Miami, Florida 33143, United States
  • Behavioral Clinical Research , Inc
    North Miami, Florida 33162, United States
  • Clinical NeuroScience Solutions Inc
    Orlando, Florida 32801, United States
  • Compass Research LLC
    Orlando, Florida 32806, United States
  • Emory University
    Atlanta, Georgia 30022, United States
  • Radiant Research, Inc.
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Joliet Center for Clinical Research
    Joliet, Illinois 60435, United States
  • Clinilabs
    New York, New York 10019, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Clinical Trials of America
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Neuro Behavioral Clinical Research
    Canton, Ohio 44708, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
  • Mental Health Center Prof. Dr. Ivan Temkov
    Burgas, 8000, Bulgaria
  • State Psychiatric Hospital Kardzhali
    Kardzhali, 6600, Bulgaria
  • State Psychiatric Hospital - Lovech
    Lovech, 5500, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • MC 'Hipokrat - N', EOOD
    Plovdiv, 4002, Bulgaria
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1202, Bulgaria
  • University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
    Sofia, 1431, Bulgaria
  • Medical Center 'Doverie'
    Sofia, 1632, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • State Psychiatric Hospital - Tzarev Brod
    Tzarev Brod, 9747, Bulgaria
  • Diagnostic Consulting Center Mladost - M Varna
    Varna, 9020, Bulgaria
  • Mental Health Center - Veliko Tarnovo EOOD
    Veliko Tarnovo, 5000, Bulgaria
  • Mederon Oy
    Helsinki, 00100, Finland
  • Savon Psykiatripalvelu
    Kuopio, 70110, Finland
  • Oulu Mentalcare Oy
    Oulu, 90100, Finland
  • Satakunnan Psykiatripalvelu
    Rauma, 26100, Finland
  • CHU Clermont-Ferrand - Hopital Gabriel Montpied
    Clermont Ferrand, 63000, France
  • Cabinet Medical des Drs Prizac-Desbonnet Scottez
    Douai, 59500, France
  • CHU Nimes Hopital Caremeau
    Nimes Cedex, 30029, France
  • Hopital Sainte Anne
    Paris, 75674, France
  • Centre Hospitalier Guillaume Regnier
    Rennes Cedex, 35011, France
  • Neurologische Praxis Dr. Schoell & Kollegen
    Bad Homburg, 61348, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09131, Germany
  • Universitatsklinikum Carl Gustav Carcus Dresden
    Dresden, 01307, Germany
  • Somni Bene GmbH
    Schwerin, 19053, Germany
  • Hongo Todaimae Mental Clinic
    Bunkyo-ku, 113-0033, Japan
  • Kuramitsu Hospital
    Fukuoka-shi, 819-0037, Japan
  • National Center for Global Health and Medicine Kohnodai hospital
    Ichikawa-shi, 272-8516, Japan
  • National Hospital Organization Hizen Psychiatric Center
    Kanzaki-gun, 842-0192, Japan
  • Nara Medical University Hospital
    Kashihara-shi, 634-8522, Japan
  • Senzoku Mental Clinic
    Meguro-ku, 152-0012, Japan
  • Heart Care Ginga Clinic
    Nakano-ku, 164-0012, Japan
  • Shiranui Hospital
    Omuta-shi, 836-0004, Japan
  • Seiwakai Yutaka Clinic
    Sagamihara-shi, 252-0303, Japan
  • Sangenjaya Nakamura Mental Clinic
    Setagaya-ku, 154-0004, Japan
  • Yoyogi Mental Clinic
    Shibuya-ku, 151-0051, Japan
  • Etoh Mental Clinic
    Shinagawa-ku, 141-0021, Japan
  • Nishi-Shinjuku Concieria Clinic
    Shinjuku-ku, 160-0023, Japan
  • Tamaki Clinic
    Shinjuku-ku, 160-0023, Japan
  • Shinjuku Research Park Clinic
    Shinjuku-ku, 169-0073, Japan
  • Ohwa Mental Clinic
    Toshima-ku, 170-0002, Japan
  • Sekino Hospital
    Toshima-ku, 171-0014, Japan
  • Jisenkai Hozumi Himorogi Clinic
    Toshima-ku, 171-0022, Japan
  • SHI Arkhangelsk Regional Clinical Psychiatric Hospital
    Arkhangelsk, 163530, Russian Federation
  • Sverdlov Regional Psychiatric Clinical Hospital
    Ekaterinburg, 620030, Russian Federation
  • City Clinical Psychiatric Hopsital 3
    Moscow, 107076, Russian Federation
  • FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
    Moscow, 107076, Russian Federation
  • Closed corporation 'Scientific Center of Personalized Psychiatry'
    Moscow, 119180, Russian Federation
  • First Moscow State Medical University n.a. I.M. Sechenov
    Moscow, 119991, Russian Federation
  • Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
    Omsk, 644070, Russian Federation
  • Medical and Rehabilitation Research Center Phoenix
    Rostov-on-Don, 344010, Russian Federation
  • City Psychiatric Hospital of St. Nikolay Chudotvorets
    Saint-Petersburg, 190121, Russian Federation
  • Engels psychiatric hospital
    Saratov Region, 413124, Russian Federation
  • SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky
    Saratov, 410028, Russian Federation
  • St-Petersburg Bekhterev Psychoneurological Research Institute
    St. Petersburg, 192019, Russian Federation
  • Research Institute of Mental Health
    Tomsk, 634014, Russian Federation
  • CNCE'Precarpathian Regional Clinical Mental Health Center Ivano-Frankivsk RC'
    Ivano-Frankivsk, 76014, Ukraine
  • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
    Kharkiv, 61068, Ukraine
  • Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa)
    Kyiv, 2660, Ukraine
  • CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'
    Lviv, 79021, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65006, Ukraine
  • CNCE Odesa regional psychiatric hospital #2 Odesa regional council
    Oleksandrivka, 67513, Ukraine
  • Poltava O.F. Maltsev RC Psychiatric Hospital Dept #9 (Ad-P Dept) HSEIU Ukrainian MSA
    Poltava, 36006, Ukraine
  • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • CI O.I. Yuschenko VRPsH Depts #7 & #10 M.I. Pyrogov VNMU
    Vinnytsia, 21005, Ukraine

Showing the first 100 of 101 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, Drevets WC. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. Int J Neuropsychopharmacol. 2021 Dec 8;24(12):965-976. doi: 10.1093/ijnp/pyab050. PubMed 34324636 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jan 2019, 16 months.

Results were first posted in Feb 2022, 3 years after primary completion. A results delay was requested in Jan 2020.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 16 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2017
First posted
Jul 24, 2017
StartActual
Aug 16, 2017
Primary completionActual
Jan 12, 2019
CompletionActual
Jan 19, 2019
Results delay requested
Jan 8, 2020
Results first posted
Feb 7, 2022
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03227224
Responsible party
Sponsor
First posted
Jul 24, 2017
Start date
Aug 16, 2017
Primary completion
Jan 12, 2019
Completion
Jan 19, 2019
Results posted
Feb 7, 2022
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion